|Dr. Gregory A. Demopulos||Co-Founder, Chairman, CEO & Pres||813.81k||N/A||1959|
|Mr. Michael A. Jacobsen||Chief Accounting Officer, VP of Fin. & Treasurer||369.95k||N/A||1958|
|Mr. Peter B. Cancelmo J.D.||VP, Gen. Counsel & Corp. Sec.||307.91k||N/A||1979|
|Dr. Pamela Pierce Palmer||Co-Founder||N/A||N/A||1963|
|Dr. George A. Gaitanaris M.D., Ph.D.||Chief Scientific Officer & VP of Science||N/A||N/A||1957|
|Mr. Peter W. Williams||VP of HR||N/A||N/A||1968|
|Dr. J. Steven Whitaker||VP of Clinical Devel. & Chief Medical Officer||N/A||N/A||1956|
|Dr. Catherine A. Melfi||Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems||N/A||N/A||1959|
|Ms. Nadia Dac||Chief Commercial Officer||N/A||N/A||1970|
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation’s ISS governance QualityScore as of 30 April 2021 is 6. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 5; Compensation: 6.